Recently, according to the result released on the website of Center for Drug Evaluation, NMPA, Tafluprost Eye Drops produced by Chengdu Suncadia Medicine Co., Ltd in Tianfu Life Science Park has been included in the list of priority review varieties. The publicity period lasts for 7 days. It is included because the drug registration application is of urgent clinical need and market shortage.

Photo source: CDE official website

On January 10, 2020, the Drug Evaluation Center of the National Medical Products Administration undertook the application for drug registration submitted by Chengdu Suncadia Medicine Co., Ltd. As of now, Chengdu Suncadia Medicine Co., Ltd has invested approximately RMB 14.47 million in research and development on this R&D project.

Tafluprost is a kind of prostaglandin analogue and a selective FP prostaglandin receptor agonist, which can reduce the intra-ocular pressure by increasing the aqueous humor outflow of the uveal sclera pathway. It is used to reduce the intra-ocular pressure for open-angle glaucoma patients and ocular hypertension patients. After being on medication, it will act on the uveoscleral pathway of aqueous humor drainage, loosening the tissue gap and reducing the resistance of glaucoma drainage. Therefore, it can promote the liquid outflow generated in the eye and reduce the intraocular pressure.

At present, anti-glaucomatous drugs, lasers and surgery are the three major clinical treatments for glaucoma. Prostaglandin eye drops are the first-line recommended drugs presented in the glaucoma treatment guidelines.

At present, there are no generics of tafluprost eye drops approved for listing in China. There are few producers of this variety, except for Suncadia Medicine and Sichuan Kelun Pharmaceutical Co., Ltd.  This time, Suncadia Medicine's listing application for tafluprost eye drops to be included in the priority review list means that the drug is expected to be approved and enter the market officially in advance, thereby bringing new options to more glaucoma patients.

About Chengdu Suncadia Medicine Co., Ltd

Founded on March 23, 2011, Chengdu Suncadia Medicine Co., Ltd is a subsidiary of Jiangsu Heng Rui Pharmaceutical Co., Ltd, comprising Chengdu Suncadia R&D Center and Chengdu Suncadia Preparation Factory.

Chengdu Suncadia R&D Center is located in Tianfu Life Science Park, High-tech Zone. It is mainly engaged in the development of multiple innovative drugs with independent intellectual property rights and high-quality generic drug research, such as anti-tumor drugs, surgical drugs, sex hormones and other medications for treating various diseases. As of 2019, it has applied for more than 50 new drug registrations.

Source: Yi Yao Guan Lan and Drug News